| Similar Articles |
|---|
 |
The Motley Fool
April 14, 2011
Brian Orelli |
Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year.   |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
Bio-IT World
September 9, 2002
Malorye Branca |
The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
August 24, 2007
Brian Orelli |
Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
The Motley Fool
November 12, 2010
Brian Orelli |
Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week. |
The Motley Fool
March 31, 2010
Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Lupus: How Big will Benlysta Become? Human Genome Sciences/GSK's Benlysta (belimumab) was approved by an FDA advisory committee in November -- to the cheers of many patients who had testified to their need of the novel therapy. |
Bio-IT World
October 9, 2002
Kevin Davies |
Cracking the 'Druggable Genome' How many potential drug targets are encoded in the human genome? It is a crucial question for every biopharma business. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
November 17, 2010
Brian Orelli |
52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Managed Care
May 2001
Michael D. Dalzell |
Powerful Opportunities For Good and Greed Genetic advances could spawn incredible improvements in health care. Given public demand, they also pose what may be unmanageable issues of resource use... |
BusinessWeek
June 13, 2005
John Carey |
The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications. |
The Motley Fool
September 29, 2011
Brian Orelli |
Are HIV Drugmakers Doomed? Generics are a bigger threat than Sangamo for now. |
Wired
September 22, 2008
Katharine Gammon |
Leroy Hood: Look to the Genome to Rebuild Health Care The 69-year-old biotechnologist bases his health care plan on the four Ps -- medicine that is predictive, preventive, personalized, and participatory. |
The Motley Fool
October 3, 2011
Brian Orelli |
About That Developing Technology... Sangamo's diabetic neuropathy drug, SB-509, fails to impress. |
BusinessWeek
April 12, 2004
John Carey |
Gene-Based Therapy: Back To The Couch Recent setbacks show (again) that biotech needs more patience and less ballyhoo |
BusinessWeek
September 5, 2005 |
Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
Pharmaceutical Executive
February 1, 2014
William Looney |
Takeda' Oncology Taskmaster Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge; and a lead position in the hotly contested search to make cancer a treatable disease. |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
Managed Care
November 2006
Maureen Glabman |
Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
The Motley Fool
December 31, 2009
Brian Orelli |
Make Money Even When Drugs Fail Biotech growth potential without as much risk can come from innovations that help drugmakers discover new drugs. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
BusinessWeek
February 10, 2011
Rob Waters |
Sangamo's Bet Against AIDS: Gene Therapy Sangamo's stock has more than doubled since July 6, when the company, with no products on the market, reported success of its gene therapy approach in mice in the journal Nature Biotechnology. |
The Motley Fool
February 28, 2011
Brian D. Pacampara |
Next-Generation Drug Technologies Battle It Out Alnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease. |
Fast Company
David Lumb |
Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period. |
Fast Company
September 2000
John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
Chemistry World
November 4, 2009
Phil Taylor |
New treatment hope for lupus patients GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab), works by blocking the production of autoantibodies by plasma B-cells, the immune system's primary antibody-producing cells. |
The Motley Fool
September 30, 2011
Brian Orelli |
We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta. |
Bio-IT World
August 2005 |
Best Practices 2005 Winners Winners of the Best Practices awards include an innovative drug safety monitoring system, an integrated genomics gateway, and a genotyping pipeline. |
The Motley Fool
November 2, 2009
Brian Orelli |
Finally Convinced? Benlysta Works! Human Genome Sciences succeeds where others have failed. |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
Wired
November 17, 2007
Thomas Goetz |
23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons. |
The Motley Fool
October 30, 2009
Brian Orelli |
Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening. |
The Motley Fool
June 15, 2005
Bobby Shethia |
A New Test for Quest The medical testing leader hopes to improve its steady performance via the rapidly growing gene-testing market. But sustained growth will require hefty capital expenditures. Investors, take note. |
The Motley Fool
April 27, 2005
Tim Hanson |
Quest for Value and Growth Quest Diagnostics, a consistent winner, could be good medicine for your portfolio. |
The Motley Fool
December 6, 2010
Brian Orelli |
3-Month Delay? No Problem! Investors shrug off HGS' Benlysta delay. The Food and Drug Administration's delaying its decision on whether to approve Human Genome Sciences and GlaxoSmithKline's Benlysta shouldn't come as much of a surprise. |
Pharmaceutical Executive
July 1, 2006
Deborah Dunsire |
Thoughtleader: Targeted Expansion Millennium Pharmaceuticals' CEO discusses what's ahead for the company, its success through partnerships, and why it believes it can lead the pack in targeted therapeutics. |
AskMen.com
Jacob Franek |
Genetic Testing Every day the prospect of individualized genetic testing is slowly becoming commonplace, and certain questions about genetic testing are apparent: What kinds of tests are available? Where can I get them? How accurate are they? And what are the costs? |
The Motley Fool
November 17, 2011
Brian Orelli |
In Biotech, Approval's Important, but It's the Launch That Counts With an approval in hand, Incyte's investors are still nervous. |
